To assess the feasibility of implementing a redispensing process for novel oral anticancer agents (NOACA) unused by patients in daily practice, by determining the cost savings thereof and identifying patient and stakeholder views on implementation of redispensing.
Redispensing unused NOACA could lead to cost savings.
A multicenter study will be conducted in four hospitals that include a prospective intervention study to determine the cost savings and qualitative research methods to identify patient and stakeholder barriers and facilitators.
Adult patients receiving NOACA from the outpatient pharmacy.
Patients receive NOACA wrapped in a sealed bag with a temperature logger and are requested to return these if remaining unused. Returned NOACA is redispensed by pharmacy staff when: the sealed bag is returned unopened, the packaging is undamaged, the expiry date is not passed, and the storage temperature is not exceeded. Prior to the intervention focus groups with patients are held to identify their perceived barriers and facilitators towards redispensing, to obtain in depth knowledge on their views and to adjust the intervention to their needs if necessary. Also focus groups with stakeholders are held to discuss the prerequisites to enable broad implementation of the intervention.
Primary outcome includes the cost savings obtained with redispensing unused NOACA, corrected for the additional pharmacy’s processing costs, as well as patients and stakeholders views, including barriers and facilitators, on implementation of redispensing in practice.
1150 patients will be included to redispense medication worth €500.000 in total. Cost savings will be corrected for the additional pharmacy’s processing costs required for redispensing. Qualitative data will be analysed using thematic content analysis.